A Plan C for Plan B: A Feminist Legal Response to the Ways in Which Behind-the-Counter Emergency Contraception Fails Women by Allen, Amanda L.
City University of New York Law Review 
Volume 11 Issue 2 
Summer 2008 
A Plan C for Plan B: A Feminist Legal Response to the Ways in 
Which Behind-the-Counter Emergency Contraception Fails Women 
Amanda L. Allen 
CUNY School of Law 
Follow this and additional works at: https://academicworks.cuny.edu/clr 
 Part of the Law Commons 
Recommended Citation 
Amanda L. Allen, A Plan C for Plan B: A Feminist Legal Response to the Ways in Which Behind-the-
Counter Emergency Contraception Fails Women, 11 N.Y. City L. Rev. 401 (2008). 
Available at: 10.31641/clr110216 
The CUNY Law Review is published by the Office of Library Services at the City University of New York. For more 
information please contact cunylr@law.cuny.edu. 
A Plan C for Plan B: A Feminist Legal Response to the Ways in Which Behind-the-
Counter Emergency Contraception Fails Women 
Acknowledgements 
The author would like to thank Professor Caitlin E. Borgmann for her invaluable guidance in developing 
this Comment and for her position as an inspirational role model for feminist law students. The author 
would also like to thank Professor Ruthann Robson for her support and guidance through the writing and 
editing process. The author would finally like to thank the pro-choice activist community for its tireless 
efforts to improve access to emergency contraception. Making Plan B available without a prescription 
has helped to prevent unwanted and unintended pregnancies for countless women, including the author, 
and has facilitated the self-determination required to plan whether and when to have a family to women 
everywhere. For these reasons, access to Plan B is a legal issue that merits attention and requires 
continued examination and advocacy against discriminatory restriction of access. 
This article is available in City University of New York Law Review: https://academicworks.cuny.edu/clr/vol11/iss2/17 
A PLAN C FOR PLAN B: A FEMINIST LEGAL




Later I went back and asked the pharmacist why she wouldn’t distribute
[Plan B], and she said . . . it was against her religion, . . . .  And I
asked her why, and she said, “I don’t believe in abortion.”1
A society in which women lack control to plan when they have children is
one in which women must remain second-class citizens.2
INTRODUCTION
On August 24, 2006, the Food and Drug Administration
(“FDA”) approved Plan B, the brand-name drug sold for emer-
gency contraception, for sale to pharmacy customers eighteen and
over without a prescription.3  For the first time in FDA history, “a
* Fellow, Law Students for Reproductive Justice, 2008–2009.  J.D., City University
of New York School of Law, 2008.  B.A., University of Minnesota, 2004.  The author
would like to thank Professor Caitlin E. Borgmann for her invaluable guidance in
developing this Comment and for her position as an inspirational role model for
feminist law students.  The author would also like to thank Professor Ruthann Robson
for her support and guidance through the writing and editing process.  The author
would finally like to thank the pro-choice activist community for its tireless efforts to
improve access to emergency contraception.  Making Plan B available without a pre-
scription has helped to prevent unwanted and unintended pregnancies for countless
women, including the author, and has facilitated the self-determination required to
plan whether and when to have a family to women everywhere.  For these reasons,
access to Plan B is a legal issue that merits attention and requires continued examina-
tion and advocacy against discriminatory restriction of access.
1 Interview with Carrie Baker, a Kroger customer who was refused Plan B in De-
cember 2006, June 12, 2007, http://www.youtube.com/watch?v=j5iicsr_19g (last vis-
ited Apr. 30, 2008).
2 Cornelia T. L. Pillard, Our Other Reproductive Choices: Equality in Sex Education,
Contraceptive Access, and Work-Family Policy, 56 EMORY L.J. 941, 975 (2007).
3 See Letter from Steven Galson, Dir., FDA Ctr. for Drug Evaluation & Research,
to Joseph A. Carrado, Vice President, Clinical Regulatory Affairs, Duramed Research,
Inc., http://www.fda.gov/cder/foi/nda/2006/021045s011_Plan_B_APPROV.pdf.  In
its letter to the manufacturer of Plan B, which requested Plan B’s approval for over-
the-counter use, the FDA decided that “Plan B is safe and effective for use under the
conditions set forth in the draft labeling submitted on August 23, 2006. This applica-
tion is approved, effective on the date of this letter, to allow OTC availability of Plan B
for consumers 18 years and older. Plan B remains available by prescription only for
women 17 years and younger.” Id. at 2. The letter further determined that “[t]he
sponsor and third party distributors, wholesalers, and chain drug companies will only
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drug for which no prescription is required is available only in phar-
macies and health clinics.”4  Further, by regulation, Plan B must be
shelved behind the pharmacy counter; thus, a customer over the
age of eighteen seeking this medication must still ask a pharmacist
for it and show photo identification with proof of age in order to
obtain it.5  A pharmacist with a “moral” or religious objection to
emergency contraception can, therefore, still pose a barrier to a
customer seeking to obtain it.6  My purpose in writing this Com-
ment is to challenge both the actions of refusing pharmacists and
the rule itself from a feminist legal perspective by mapping out a
litigation strategy for women affected by the rule’s shortcomings.
In this Comment, I argue that the regulation permitting be-
hind-the-counter sale of Plan B to customers over the age of eigh-
teen precludes women from taking full advantage of the
reproductive health services available to them, interferes with their
right to choose whether and when to have children, and treats wo-
men differently than men as users of the medication while para-
doxically on the same footing as purchasers.  This Comment
addresses two problems with the regulation.  First, because the rule
permits only behind-the-counter (rather than pure over-the-
counter) sale of Plan B, pharmacists are in a unique position to
decide whether they think the customer should receive the re-
quested medication.  Second, the rule surreptitiously adds an age
requirement that was neither contemplated by the manufacturer
distribute Plan B to licensed pharmacies or other licensed healthcare clinics. As a
result, Plan B will not be sold at gas stations or convenience stores. Given that Plan B
will have both Rx and OTC [over-the-counter] labeling, the pharmacies will keep Plan
B behind-the-counter.” Id. at 3.
4 Brief of Plaintiffs, Tummino v. Von Eschenbach, 427 F. Supp. 2d 212 (E.D.N.Y.
argued Mar. 31, 2007) (No. CV 05-366 ERK/VVP), 2007 WL 1143253, at *1.
5 Id.; see also Plan B: Questions and Answers, http://www.fda.gov/cder/drug/
infopage/planB/planBQandA20060824.htm [hereinafter Plan B: Questions and An-
swers] (last updated Dec. 14, 2006).  True over-the-counter medications, by contrast,
are “drugs that are available to consumers without a prescription” and those that “can
be used without the help of a health care practitioner.”  Over-the-Counter Drug Prod-
ucts, http://www.fda.gov/cder/handbook/otcintro.htm (last visited Mar. 3, 2008).
The FDA notes that over-the-counter drugs generally share the following characteris-
tics: “[T]heir benefits outweigh their risks[;] their potential for misuse and abuse is
low[;] [the] consumer can use them for self-diagnosed conditions[;] they can be ade-
quately labeled[;] [and] health practitioners are not needed for the safe and effective
use of the product.”  Office of Nonprescription Products, http://www.fda.gov/cder/
Offices/OTC/default.htm (last visited Mar. 3, 2008).
6 One study revealed 180 refusals of this nature in the six-month period surveyed
in 2004.  Editorial, Moralists at the Pharmacy, N.Y. TIMES, Apr. 3, 2005, at D2; see also
Stormans, Inc. v. Selecky, 524 F. Supp. 2d 1245 (W.D. Wash. 2007) (granting a prelim-
inary injunction enjoining enforcement of Washington State regulations prohibiting
a pharmacist from refusing fill a lawful prescription for religious or moral reasons).
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nor medically justified, which hinders the access of young women
and women without the required identification.
Part I of this Comment begins with an overview of Plan B as a
drug, including a brief summary of the passage of the rule that
allows behind-the-counter sale of Plan B, and considers its role in a
larger political movement in which conservative lawmakers have at-
tacked a woman’s right to choose whether and when to have chil-
dren from every imaginable perspective—including opposition to
ordinary contraceptives.  Part I also provides a feminist legal per-
spective to restrictions on women’s reproductive choice.  Part II of
this Comment considers three broad ways to think about challeng-
ing the problem of pharmacy refusals, using New York law as a
model.  This Part explores various theories of relief upon which
women who have been denied over-the-counter emergency contra-
ception by a pharmacist exercising moral, instead of medical, judg-
ment may recover.  Part II concludes by considering the First
Amendment implications of holding pharmacists civilly liable for
refusing to dispense emergency contraception.  Part III of this
Comment discusses a lawsuit which challenges the rule’s age re-
striction, problematizing in particular the way in which the age re-
striction privileges both age (adults) and gender (male purchasers/
non-users) in ways that are unrelated to the use of the drug or its
risks.  Part III concludes by reintegrating a feminist legal theoreti-
cal perspective to the argument that the age restriction is unwar-
ranted and by reiterating the importance of a feminist legal agenda
that can affect change in women’s lives.
I. BACKGROUND
The problem of pharmacist refusals is situated culturally in a
time in which interrelated fears of non-procreative sex and sexually
independent women are particularly pervasive and politicized.7 It
has not just been emergency contraception that has received vigor-
ous opposition from the religious right; cultural conservatives
steadfastly oppose comprehensive sex education and virtually all
7 See generally CRISTINA PAGE, HOW THE PRO-CHOICE MOVEMENT SAVED AMERICA:
FREEDOM, POLITICS AND THE WAR ON SEX (2006).  Page explicitly rejects the notion of
isolated, individual pharmacists acting on their own moral imperatives in denying
emergency contraception and instead points to a broader cultural phenomenon:
“[T]hese are not random acts.  Behind each are the force and rhetoric of the pro-life
movement.” Id. at 3–4.  Page argues that the conservative right’s stance on abortion
has blossomed into a war on birth control, sex education, and non-procreative sex in
general in an effort to “end the lifestyle in which people have sex just for pleasure.”
Id. at 6, 29.
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forms of birth control, including the condom.8 Indeed, in a time
where federal guidelines suggest women of child-bearing age, and
the medical professionals treating them, to be “pre-pregnant,”9 it is
not surprising that the religious right has supported measures that
would prevent or severely debilitate access to emergency contra-
ception.  Opponents of over-the-counter emergency contraception
have argued that it is unsafe,10 will help spread sexually transmitted
diseases,11 causes abortions,12 and even will encourage women to
8 Id. at 83–97.  Page argues that the anti-choice movement relies on faulty data to
support its contention that condom use fails to protect against HIV transmission. Id.
at 83–85.  The pro-life movement often cites a “31% failure rate” statistic based on a
flawed University of Texas study on HIV transmission rates and condom use that was
later corrected by the Centers for Disease Control and Prevention. Id. at 83.  Page
argues that the pro-life movement ignores science because it “fears that the availabil-
ity of effective disease-prevention methods will undermine its larger agenda, promot-
ing a world in which people are either abstinent or making babies.” Id. at 85. See also
Condom Warnings—Beware!!!, http://www.prolife.com/condoms.html (last visited
Apr. 14, 2007) (claiming that “[t]he average condom failure rate in the 11 [University
of Texas] studies for preventing transmission of the AIDS virus was 31%” and “a vari-
ety of studies have found that condoms have an ‘annual failure rate’ of 10% to 36%
when it comes to preventing pregnancy”); UNITED FOR LIFE, COULD CONDOMS LEAK
HIV? (2003), http://www.unitedforlife.com (follow Leaflets hyperlink) (last visited
Feb. 24, 2007) (“Since women can only get pregnant during 5-7 days, (1/4) of their
28 day menstrual cycle, and cannot get pregnant during the other 21 days, these con-
dom failure rates could be multiplied by four to get the ‘overall failure rate’ which
gives at least a 60% failure rate for the average population of condom users and at
least an 80% failure rate for young teenagers.”).  This cultural conservativism is re-
flected in federal funding for abstinence programs. See Kim Shayo Buchanan, Law-
rence v. Geduldig: Regulating Women’s Sexuality, 56 EMORY L.J. 1235, 1259-60 (2007)
(describing “abstinence-only-until-marriage” programs which are “required to sup-
press all information about condoms and other modern forms of contraception, ex-
cept failure rates.”).
9 January W. Payne, Forever Pregnant: Guidelines: Treat Nearly All Women as Pre-Preg-
nant, WASH. POST, May 16, 2006, at F1, available at http://www.washingtonpost.com/
wpdyn/content/article/2006/05/15/AR2006051500875_pf.html (“New federal
guidelines ask all females capable of conceiving a baby to treat themselves—and to be
treated by the health care system—as pre-pregnant, regardless of whether they plan to
get pregnant anytime soon.”).
10 See, e.g., MOIRA GAUL & CHRIS GACEK, PLAN B: A GRAVE THREAT TO WOMEN’S
HEALTH 1–2 (Family Research Council 2006), available at http://www.physiciansfor
life.org/content/view/1161/36/ (last visited Apr. 7, 2008) (citing concerns about the
“clear lack of scientific studies on the long-term-effects of Plan B”). See also PAGE,
supra note 7, at 110–11.  During a December 2003 joint meeting of FDA advisory
panels to review the Plan B application, panelist David Hager, the pro-life obstetri-
cian-gynecologist and chair of the Physicians Resources Council at Focus on the Fam-
ily, expressed grave concerns that the safety of emergency contraception had not yet
been adequately established for a nine or ten-year-old girl. Id. at 105–10.
11 PAGE, supra note 7, at 113 (noting that forty-nine pro-life members of Congress
urged President Bush in a letter to reject Barr’s application to make Plan B available
over the counter because “easier access to EC ‘may ultimately result in significant
increases in cancer, infertility, and HIV/AIDS.’”). See also GAUL & GACEK, supra note
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fabricate rape allegations in order to obtain emergency contracep-
tion in the hospital.13
In reality, the concerns of opponents of over-the-counter
emergency contraception are largely overstated and serve to mask
the need for unencumbered access to Plan B.  Plan B is safe and
effective.14 Plan B does not cause abortions.15  Plan B works by
preventing the release of an egg from the ovary, or by preventing
fertilization or implantation, and does not affect an already-fertil-
10, at 2 (claiming that STD rates have “skyrocketed” in countries where Plan B has
been deregulated).
12 See, e.g., Hearing Before the Nonprescription Drugs Advisory Comm. and Advi-
sory Comm. for Reproductive Health Drugs (Dec. 16, 2003) (statement of Judie
Brown, President of American Life League), available at www.fda.gov/ohrms/dock-
ets/ac/03/transcripts/4015T1.doc.  Brown stated in her testimony before the joint
advisory committees to the FDA that emergency contraception “act[s] to prevent
pregnancy by aborting a child.  For this reason alone the pill should not be available
under any circumstance and certainly not over the counter.” Id. at 204.
13 Julia C. Martinez, Seeking Court Help on Amendment 41, DENVER POST, Feb. 4,
2007, available at  http://www.denverpost.com/opinion/ci_5157469.  Martinez re-
ported that Colorado State Senator David Schultheis, at a Senate Health and Human
Services Committee hearing, “asked the sponsor of a bill requiring hospitals to give
information on emergency contraception to rape victims how doctors ‘determine that
a person actually did incur that sexual assault. Are they going to take the word of that
individual?’ ” Id.  Senator Schultheis was then reported to have said, “ ‘You could see
individuals coming in that just wanted to make sure that last night’s [one-night] stand
didn’t result in a pregnancy and basically say that they had been a sexual assault [vic-
tim]’ to get the contraceptive.” Id.
14 See, e.g., David G. Weismiller, Emergency Contraception, 70 AM. FAMILY PHYSICIAN
707, 710 (2004) (“the true effectiveness rate [of emergency contraception] is likely to
be at least 75 percent.”).  In terms of safety, “[n]o contraindications to hormonal
emergency contraception exist.”  David A. Grimes & Elizabeth G. Raymond, Emergency
Contraception, 137 ANNALS OF INTERNAL MEDICINE 180, 183 (2002). See also Taunya
English, Emergency Contraception Does Not Reduce Unintended Pregnancy Rate, HEALTH BE-
HAVIOR NEWS SERVICE, Apr. 17, 2007, http://www.hbns.org/getDocument.cfm?
documentID=1483 (last visited Feb. 11, 2008) (“advance provision of [emergency con-
traception] has no harmful effects in terms of risky sexual behaviors.”) (quoting Chel-
sea Polis, Department of Population, Family and Reproductive Health, Johns Hopkins
Bloomberg School of Public Health).  Ms. Polis was lead reviewer on a study “evaluat-
ing advance provision of emergency contraception to explore effects on pregnancy
rates, sexually transmitted infections, and sexual and contraceptive behaviors.” See
Chelsea A. Polis et al., Review, Advance Provision of Emergency Contraception for Pregnancy
Prevention: A Meta-Analysis, 110 OBSTETRICS & GYNECOLOGY 1379 (Dec. 2007).
15 See DURAMED PHARMACEUTICALS, INC., BARR PHARMACEUTICALS, INC., PRODUCT IN-
FORMATION FOR PLAN B 7 (2006), available at http://www.fda.gov/cder/foi/label/
2006/021045s011lbl.pdf [hereinafter PRODUCT INFORMATION FOR PLAN B] (“There is
no medical evidence that Plan B would harm a developing baby.  If you take Plan B
accidentally after you are already pregnant, or it does not work and you become preg-
nant, it is not likely to cause any harm to you or your pregnancy.  Plan B should not
have any effect on a pregnancy after implantation.”) (original product packaging and
information on file with author). See also Weismiller, supra note 14, at 709 (“The data
do not suggest that use of oral contraceptives can interrupt an established
pregnancy.”).
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ized egg that has attached to the uterus.16  Plan B also has no
known contraindications.17  Studies indicate that even the repeated
use of emergency contraception is unlikely to be harmful.18  What
is indisputably true about emergency contraception, besides that it
is safe, effective, and prevents unwanted pregnancies, is its time-
sensitive nature.19  Plan B must be taken “as soon as possible, but
no later than [three] days . . . after unprotected sex.”20  Especially
for women living in rural areas and women who do not have access
to convenient or inexpensive transportation, barriers such as phar-
macist refusals and the identification requirement pose problem-
atic obstacles to women seeking emergency contraception.21
Not only is emergency contraception completely safe and ef-
fective on an individual patient level, but its availability would also
benefit society at large.  It is estimated that the widespread use of
emergency contraception could prevent approximately two million
unplanned pregnancies and one million abortions each year in the
16 Plan B: Questions and Answers, supra note 5; see also Grimes & Raymond, supra
note 14.  Grimes and Raymond explain:
When taken before ovulation, emergency contraceptive pills prevent
ovulation in some women . . . .  Additional mechanisms proposed for
medical emergency contraception regimens include changes to the cer-
vical mucus that result in trapping of sperm; alterations in the transport
of sperm, egg, or embryo through the reproductive tract; interference
with corpus luteum function; and direct inhibition of fertilization.
Id. at 182.
17 Grimes & Raymond, supra note 14, at 183; see also Weismiller, supra note 14, at
710–11 (noting that, according to the World Health Organization, pregnancy is a
contraindication, and the American College of Obstetricians and Gynecologists iden-
tify three possible additional contraindications).
18 Grimes & Raymond, supra note 14, at 186.
19 Weismiller, supra note 14, at 707 (2004) (“Immediate use of an emergency con-
traceptive reduces a woman’s risk of pregnancy to 1 to 2 percent.”). See also id. at 709.
20 PRODUCT INFORMATION FOR PLAN B, supra note 15, at 6.  However, there is evi-
dence that Plan B works up to five days after unprotected sex. See, e.g., Grimes &
Raymond, supra note 14, at 183.
21 ACLU OF KENTUCKY, EMERGENCY CONTRACEPTION ACCESS: A SURVEY OF KENTUCKY
PHARMACIES (Mar. 9, 2007), http://aclu-ky.org/content/view/192/59 (last visited
Apr. 28, 2008). The findings of the Kentucky ACLU after doing a survey of state phar-
macies was that “[s]ix counties offered no access to Plan B at all.  This is a serious
problem for any woman seeking a time sensitive medication, but especially for women
in rural areas where the closest pharmacy with Plan B in stock could be 100 miles
away.” Id.  See also NARAL PRO-CHOICE WASHINGTON FOUNDATION, 2008 EMERGENCY
CONTRACEPTION ACCESS PROJECT REPORT, http://www.prochoicewashington.org/
assets/files/ecaccessprojectfactsheet.pdf (“In rural areas, the distance between phar-
macies can be a serious burden. The availability, time and cost of transportation are
all factors that can negatively impact a woman’s ability to travel to multiple pharma-
cies in hopes of receiving a needed, time-sensitive medication.”).
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United States alone.22  Convenient and unencumbered access to
emergency contraception is also vital for survivors of rape.23
Attempts to limit women’s access to emergency contraception
are not related to science, they are not about medicine, and they
are not about protecting women’s health.  Beneath the rhetoric
about drug safety and concern about sexually transmitted diseases
(but without providing any real options about disease prevention
beyond abstinence)24 lies a deep-seated fear of sexually autono-
mous women making choices about their bodies and their lives.25
The ideological encouragement and legal support of barriers to
access to emergency contraception is a telling illustration of the
religious right’s thinly-veiled contempt for women.26
A. The Morning-After Conspiracy27
The process by which Plan B obtained behind-the-counter ap-
proval from the FDA was both highly politicized and highly
gendered.28  Distrust and disdain for women are apparent in the
saga of Plan B’s approval for behind-the-counter purchase.  This
section provides a brief overview of the irregularities in the FDA’s
decisionmaking regarding making Plan B available over-the-
counter.29
22 James Trussell et al., Emergency Contraceptive Pills: A Simple Proposal to Reduce Unin-
tended Pregnancies, 24 FAM. PLAN. PERS. 269, 270 (1996).
23 See Planned Parenthood—Refusal Clauses: A Threat to Reproductive Rights,
http://www.plannedparenthood.org/issues-action/birth-control/refusal-clauses-654
4.htm (last visited Mar. 3, 2008) (“An estimated 25,000 unintended pregnancies each
year are a result of sexual assault. Approximately 22,000 of these pregnancies could be
prevented if all women who were raped were provided with [emergency
contraception].”).
24 See, e.g., PAGE, supra note 7, at 69–70 (discussing abstinence-only programs in
Texas during Bush’s term as governor).
25 See generally id. at 121–44 (“They [pro-life groups such as Population Research
Institute] feared that women, availing themselves of family planning, might partici-
pate as equals in society. The real worry was that these women would become inde-
pendent and ambitious, thinking and acting for themselves.”) Id. at 143.
26 See id.
27 The Morning-After Pill conspiracy is a “coalition of feminist organizations that
have been leading the grassroots charge to make the morning-after pill available over-
the-counter for all women.” DARA MAYERS, CTR. FOR REPRODUCTIVE RIGHTS, MORNING-
AFTER PILL CONSPIRACY: INTERVIEW WITH ANNIE TUMMINO (2006), http://www.
reproductiverights.org/crt_contraception_ec_tummino.html (last visited Apr. 28,
2008).
28 See, e.g., Buchanan, supra note 8, at 1239–54 (arguing that “[s]exual regulation
has always been gendered” as manifested in paternity laws, obscenity jurisprudence,
and the criminalization of sex toys).
29 For a more in-depth analysis of the FDA’s process in reviewing the Plan B appli-
cations for over-the-counter approval, see PAGE, supra note 7, at 99–119. See also Gil-
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Plan B was first approved for prescription use in 1999.30  In
2001, the Center for Reproductive Rights, on behalf of a group of
women’s health and medical associations, filed a Citizen’s Petition
requesting that the FDA switch Plan B and another emergency con-
traceptive drug, Preven, from prescription to over-the-counter sta-
tus.31  The FDA delayed action on this “switch” petition for five
years and finally denied it on June 9, 2006.32  This denial was issued
during discovery in Tummino v. von Eschenbach,33 filed on January
21, 2005, in which plaintiffs challenged the FDA’s failure to make
Plan B available over-the-counter for women of all ages.
In April 2003, Women’s Capital Corporation submitted an ap-
plication to the FDA requesting the same relief from the FDA: ap-
proval of Plan B for pure over-the-counter (“OTC”) use.34  In
December 2003, FDA’s joint advisory committee voted to approve
this application in a vote of twenty-three to four.35  Additionally,
FDA review staff “agreed that Plan B should be granted OTC sta-
tus.”36  However, on May 6, 2004, the Acting Director for the FDA’s
Center for Drug Evaluation and Research signed a letter denying
this application, in direct conflict with the recommendations of the
two FDA committees.37
The Government Accountability Office (“GAO”) reviewed the
FDA’s “not-approvable” decision because of these inconsistencies.38
In reviewing this decision, the GAO found that:
[F]our aspects of FDA’s review process were unusual: officials
who would normally have been responsible for signing an action
letter disagreed with the decision and did not sign the not-ap-
provable letter for Plan B; high-level management was more in-
lian E. Metzger, Abortion, Equality, and Administrative Regulation, 56 EMORY L.J. 865,
876–82 (2007) (describing the deviation from standard FDA procedures for Plan B’s
over-the-counter application).
30 Plan B: Questions and Answers, supra note 5. R
31 Citizen’s Petition (Feb. 14, 2001), available at http://www.reproductiverights.
org/pdf/EC_petition.pdf.
32 Letter from Randall W. Lutter, Assoc. Comm’r for Policy and Planning, Food &
Drug Admin., to Bonnie Scott Jones & Simon Heller, Ctr. for Reproductive Rights
(June 9, 2006), available at http://www.fda.gov/ohrms/dockets/dockets/01p0075/
01p-0075-pdn001-vol348.pdf.
33 427 F. Supp. 2d 212 (E.D.N.Y. 2006).
34 U.S. GOV’T ACCOUNTABILITY OFFICE, FOOD & DRUG ADMIN., DECISION PROCESS TO
DENY INITIAL APPLICATION FOR OVER-THE-COUNTER MARKETING OF THE EMERGENCY
CONTRACEPTIVE DRUG PLAN B WAS UNUSUAL 1 (2005), available at http://www.gao.
gov/new.items/d06109.pdf [hereinafter G.A.O. REPORT].
35 Id. at 2.
36 Id. at 2.
37 Id. at 13.
38 See id. at 3.
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volved than for other OTC switch applications; conflicting
accounts exist of whether the decision to not approve the appli-
cation was made before the reviews were completed; and the
rationale for the not-approvable decision was novel and did not
follow FDA’s traditional practices.39
In addition to the decision’s departure from the FDA’s usual ad-
ministrative procedures generally, the decision also departed from
the FDA’s particular patterns with respect to switch applications:
the GAO concluded that “the decision not to approve the Plan B
OTC switch application was not typical of the other 67 prescrip-
tion-to-OTC switch decisions made from 1994 through 2004.”40
The fourth aspect of the FDA’s decisionmaking that was unu-
sual, according to the GAO, is perhaps most troubling.  A part of
the novelty of the decision involved the FDA’s use of assumptions,
not data, about adolescent use of Plan B.41  For example, in provid-
ing support for its decision to deny the switch application, the Act-
ing Director of the Center for Drug Evaluation and Research
(“CDER”) expressed concerns that “increased access to Plan B
could potentially result in an increase in unsafe sexual activity, par-
ticularly among younger adolescents.”42  The CDER Acting Direc-
tor also noted that younger adolescents constitute an “age group
. . . that has a tendency to engage in risky behaviors because of
their level of cognitive development.”43  This is particularly troub-
ling because adolescents had, in fact, been studied to determine
whether they could safely take Plan B—and the adolescents studied
were able to comprehend the label just as well as adult women.44
These assumptions have translated into decreased access to Plan B
for young women.
Another aspect of the approval process that caused concern
among reproductive rights advocates was President Bush’s decision
to fill the vacancies on the FDA’s Reproductive Health Drugs Com-
39 Id. at 13.
40 Id. at 5.
41 It is crucial to ensure young women have access to contraceptive services, as
various factors particular to young women, including age, income, and family rela-
tionships, interact in contributing to the prevalence of teen pregnancy.
42 G.A.O. REPORT, supra note 34, at 23.
43 Id. at 23.
44 PAGE, supra note 7, at 111 (“Females from twelve to fifty had been sampled,
including seventy-six between twelve and sixteen years old.  Adolescents understood
60 to 97 percent of the drug-product package directions and materials, at a compre-
hension level similar to that of women as a whole and one that easily met standards
previously accepted for the approval of other over-the-counter drugs.” (citation
omitted)).
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mittee with pro-life appointees,45 appointments that played an im-
portant role in the FDA’s delay in reviewing applications to bring
Plan B over-the-counter.46  Numerous statements, made by FDA of-
ficials, suggest that the decision-making process was influenced by
conservative political and even religious ideologies, rather than the
tenets of science and medicine.  For example, Dr. W. David Hager,
a pro-life obstetrician-gynecologist appointed to serve on the FDA’s
Reproductive Health Drugs Committee, gave a speech six months
after the FDA’s initial rejection of the over-the-counter switch ap-
plication, saying:
I was asked to write a minority opinion that was sent to the com-
missioner of the FDA . . . I argued from a scientific perspective,
and God took that information, and he used it through this mi-
nority report to influence the decision.  Once again, what Satan
meant for evil, God turned into good.47
Another FDA official, Dr. Janet Woodcock, was reported to have
told a group of FDA employees—regarding agency concerns about
approving Plan B for over-the-counter use—that “‘we could not an-
ticipate or prevent extreme promiscuous behaviors such as the
medication taking on ‘urban legend’ status that would lead adoles-
cents to form sex-based cults centered around the use of Plan
B.’”48
Overall, the way in which the FDA handled the over-the-
counter switch application was palpably suspicious.  Revealingly,
U.S. Magistrate Judge Viktor Pohorelsky, in granting the Tummino
plaintiffs’ request to subpoena certain White House documents,
ruled that the plaintiffs demonstrated a “strong preliminary show-
ing of ‘bad faith or improper behavior’” by the FDA in its decision-
making around Plan B.49  Feminist legal theorists may view the
FDA decision as indicative of more than just bad faith, however:
the agency’s conduct may be symptomatic of the broader dilemma
45 Id. at 104–05.
46 Id. at 104–06 (President Bush appointed Dr. Joseph Sanford, a physician who
“refuses to prescribe the birth control pill because he believes it is ‘incompatible with
Christian values’”; Dr. Susan Crockett, co-author of the essay, “Using Hormone Con-
traceptives Is a Decision Involving Science, Scripture, and Conscience”; and Dr. W.
David Hager, who reportedly refuses to prescribe contraceptives to unmarried wo-
men, chairs the Physicians Resources Council at Focus on the Family, and advises
Concerned Women for America and the Medical Institute for Sexual Health in their
campaign against the condom).
47 Id. at 117–18.
48 See, e.g., Jon Carroll, Opinion, S.F. CHRON., May 15, 2006, at E8, available at
http://www.sfgate.com/cgi-bin/article.cgi?file=/Chronicle/archive/2006/05/15/
DDGKAIHDPR1.DTL (quoting FDA official Janet Woodcock).
49 427 F. Supp. 2d at 231–32.
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facing women’s rights advocates in which, time and time again, le-
gal norms disregard the realities and complexities of women’s lives.
At the very least, the ways in which the FDA decision privileged
antiquated views about women’s and girls’ sexuality along with the
ideological agenda of a conservative presidential administration
over science, medicine, and women’s health offers support for the
feminist critique of the law as an inherently patriarchal institution.
B. A Feminist Critique of Barriers to Reproductive Choice
Feminist legal theorists argue that access to reproductive ser-
vices is fundamental to women’s equality.50  In doing so, these fem-
inists affirm that the ability to wholly control family planning
affects a broad range of issues of import to women’s lives, includ-
ing education, employment opportunities, women’s general health
and well-being, and sexual freedom.51  Thus, a feminist legal analy-
sis of reproductive rights examines and challenges the ways in
which the laws burdening reproductive choice rely on archaic ste-
reotypes of “women’s place” in the home.52  Reproductive choice
recognizes that women do not exist merely to care for others and
recognizes women’s decisional autonomy to make the best choices
for themselves and their families.53
50 See Pillard, supra note 2, at 945 (“Reproductive rights, including the rights to
contraception and abortion, play a central role in freeing women from historically
routine conscription into maternity. It is reproductive rights that have begun to allow
women to decide whether and when to follow the path of motherhood.”); Catharine
A. MacKinnon, Reflections on Sex Equality under Law, 100 YALE L.J. 1281, 1322–28
(1991) (citing Morgenthaler v. The Queen, [1988] 1 S.C.R. 30, 172 (Wilson, J., con-
curring)) (“Reproductive control is properly ‘an integral part of modern woman’s
struggle to assert her dignity and worth as a human being.’”); Buchanan, supra note 8,
at 1269 (“[L]aws [restricting a woman’s access to contraception or abortion] burden
women with the reproductive consequences of sex when they would otherwise be free
to avoid them. With few exceptions, our laws do not do this to heterosexual men.”
(citation omitted)).
51 Reva B. Siegel, Sex Equality Arguments for Reproductive Rights: Their Critical Basis
and Evolving Constitutional Expression, 56 EMORY L.J. 815, 819 (2007) (“[Reproductive
choice] crucially affects women’s health and sexual freedom, their ability to enter and
end relationships, their education and job training, their ability to provide for their
families, and their ability to negotiate work-family conflicts in institutions organized
on the basis of traditional sex-role assumptions that this society no longer believes fair
to enforce, yet is unwilling institutionally to redress.”).
52 MacKinnon, supra note 50, at 1312–13 (“After childbirth, women tend to be the
ones who are primarily responsible for the intimate care of offspring—their own and
those of others. Social custom, pressure, exclusion from well-paying jobs, the structure
of the marketplace, and lack of adequate daycare have exploited women’s commit-
ment to and caring for children and relegated women to this pursuit which is not
even considered an occupation but an expression of the X chromosome.”).
53 See Siegel, supra note 51, at 819.
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The feminist critique of barriers to women’s reproductive
choice also problematizes the patriarchal norms which simultane-
ously privilege women’s domestic responsibility and tolerate men’s
sexual irresponsibility, and connect those norms to legal, social,
and institutional barriers to reproductive choice.  For example, le-
gal scholar Cornelia Pillard notes that “[p]eople generally still view
child rearing as women’s gratification and their domain, and ac-
cept men’s failure to do [so] and value it as personal, private
choice, off-limits to criticism.”54  Similarly, legal scholar Kim Shayo
Buchanan notes that “[t]he legal coercion of sexual morality is typ-
ically interpreted in a way that requires the control, surveillance,
and punishment of women, but rarely of men.”55
Some feminists have argued that a sex equality standpoint on
reproductive rights is crucial in that it enables people to see “how
reproductive rights are a hinge pin between liberty and equality.”56
Constitutional law scholar Reva Siegel argues that “[a] sex equality
analysis of reproductive rights views the social organization of re-
production as playing a key role in determining women’s status
and welfare and insists—custom notwithstanding—that govern-
ment regulate relationships at the core of the gender system in
ways that respect the equal freedom of men and women.”57  Siegel
further argues that a sex equality standpoint on reproductive rights
simultaneously problematizes the way in which “custom” shapes
the sex roles of men and women and destabilizes the gendered
norms that structure parenting.58  Feminist legal scholar Catharine
MacKinnon, also arguing from a sex equality standpoint, demands
a recontextualization of pregnancy from the point of view of the
pregnant woman.59  Finally, the sex equality standpoint “appreci-
54 Pillard, supra note 2, at 943. See also Buchanan, supra note 8, at 1239–40 (“While
the law extends a marked solicitude to the right of men to have nonmarital sex with-
out incurring unwanted reproductive consequences, it visits the legal, financial,
health, and reproductive burdens of unmarried sex exclusively on women and attrib-
utes the disparate treatment to nature.”) (citations omitted).
55 Buchanan, supra note 8, at 1241.
56 Pillard, supra note 2, at 941.  Pillard continues, “Women need practical access to
a range of reproductive choices to enjoy sex equality, yet they need equality to make
reproductive decisions freely and in ways that are responsible to themselves, those
they love, and the broader society.” Id.
57 Siegel, supra note 51, at 815.
58 See id. at 817–18.
59 MacKinnon, supra note 50, at 1309 (“Grounding a sex equality approach to re-
productive control requires situating pregnancy in the legal and social context of sex
inequality and capturing the unique relationship between the pregnant woman and
her fetus. . . .  The social conception of pregnancy that has formed the basis for its
legal treatment has not been from the point of view of the pregnant woman, but
rather from the point of view of the observing outsider, gendered male.”).
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ate[s] that there is both practical and dignitary significance to the
decisional control that reproductive rights afford women, and that
such control matters more to women who are status marked by rea-
son of class, race, age, or marriage.”60
Broadening the services considered to exist in the “bundle” of
reproductive rights to include contraceptive equity issues necessa-
rily recognizes that “the unwantedness of a pregnancy and the de-
mand for abortion do not occur in a vacuum.”61  Feminists oppose
laws which restrict access to contraception “to the extent that such
laws presuppose or entrench customary, gender-differentiated
norms concerning sexual expression and parenting.”62  Some femi-
nists also stress the importance of contraceptive access because of
the comparable benefits of pregnancy prevention over abortion.63
Thus, in viewing contraceptive access issues with a feminist lens, it
is clear that “[t]he law should clearly affirm women’s right to use
contraception to control when and whether they become pregnant
as an indispensable element of sex equality.”64
Various aspects of the passage of the FDA rule permitting be-
hind-the-counter sale of Plan B—from the time it took for the
agency to review the switch application to the way the rule itself
characterizes and patronizes young women—provide support for
the feminist critique of legal standards which burden women’s re-
productive choice.  The slow pace the agency took in reviewing the
various switch applications suggests that politics—not women’s
health—are the primary motivation of governmental decision-mak-
ing; these politics have a disdain for sexual autonomy and indepen-
dence of women.  The fact that the agency declined to follow its
own procedures in order to impede access to Plan B demonstrates
the government’s refusal to “[e]qually meet[ ] women’s health
needs, whether they are the same as men’s or distinctive . . .
[which] is a critical aspect of treating women as equal human be-
ings.”65  Finally, the behind-the-counter status granted to Plan B
transferred the power from the hands of the woman-consumer to
60 Siegel, supra note 51, at 819.
61 Pillard, supra note 2, at 943.
62 Siegel, supra note 51, at 821.
63 See, e.g., Pillard, supra note 2, at 963 (“Compared to abortion, contraception is
generally safer, easier on women’s bodies, more private, less expensive, and draws
fewer religious or moral objections.”) (footnote omitted).
64 Id. at 942.
65 Id. at 964 (identifying contraceptive inequality based on gender in the context
of health insurance coverage). See also MacKinnon, supra note 50, at 1323 (“Sex
equality would be advanced if women were permitted to control sexual access to their
bodies long before an unwanted pregnancy.”).
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the hands of the pharmacist, without providing protections to wo-
men for pharmacist refusals.  The next section explores the prob-
lem of pharmacist refusals—a problem whose roots lie in the FDA
rulemaking itself, as the FDA without any medical rationale in-
vented Plan B’s behind-the-counter status.66  This section explores
this problem from a legal advocacy perspective, considering the va-
rious causes of action that could be asserted against a refusing
pharmacist.
II. THE OBLIGATION OF PHARMACISTS TO DISPENSE LAWFULLY
REQUESTED MEDICATIONS: EXPLORING THE CAUSES OF ACTION
AVAILABLE AGAINST A REFUSING PHARMACIST
One of the ways in which the rule providing for behind-the-
counter access to emergency contraception is flawed is that it pro-
vides an opportunity for pharmacists to let a religious or moral ob-
jection to emergency contraception interfere with their obligation
to dispense lawfully requested medication. This section’s aim is to
provide a litigation strategy to challenge such pharmacist refusals
in a number of different contexts, using New York state law as a
model.  Each theory of relief has its strengths and has its shortcom-
ings, but they all strive to hold refusing pharmacists accountable
for breaching a duty owed to the customer.  In discussing the po-
tential forms of relief for a pharmacy customer who has been re-
fused Plan B, this section considers professional causes of action,
including professional misconduct and patient abandonment or
neglect; administrative causes of action; and private causes of ac-
tion, including sex discrimination, wrongful conception, and
breach of fiduciary duty.  This section concludes by considering
the relationship between the causes of action discussed and the
First Amendment implications of challenging pharmacist refusals.
A. Professional Causes of Action
On August 15, 2006, the New York Civil Liberties Union
(“NYCLU”) filed a complaint with the Office of the Professions at
the New York State Department of Education, the state agency re-
sponsible for regulating the licensing of pharmacists and the inves-
tigation of professional misconduct, against three pharmacists who
refused to refill prescriptions for emergency contraception pre-
scribed by a medical professional.67  The complaint alleges respon-
66 See generally G.A.O. REPORT, supra note 34, at 15–16 (providing a timeline for the
major events relating to the initial over-the-counter switch application for Plan B).
67 N.Y. CIVIL LIBERTIES UNION, REPRODUCTIVE RIGHTS PROJECT, RE: COMPLAINTS BY
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dent pharmacists violated “the New York State pharmacy laws and
regulations, professional guidelines, and New York State Human
Rights Law.”68  Although emergency contraception is now available
behind the counter for patients over the age of eighteen, the pro-
fessional causes of action alleged in the complaint are viable theo-
ries of relief for women who have been refused emergency
contraception when they try to obtain it from a pharmacist.
To file a complaint against a pharmacist, an aggrieved cus-
tomer may fill out a complaint form available at the Office of the
Profession’s web site.69  The relief available under a professional
cause of action is professional sanctions.70  A pharmacist found
guilty of professional misconduct71 or patient abandonment or
neglect72 is subject to the sanctions prescribed in New York Educa-
tion Law § 6511, including suspension, revocation, or annulment
of license and fines.73
1. Professional Misconduct
In New York, it is professional misconduct for a pharmacist to
“[p]ractice the profession . . . beyond its authorized scope.”74
Pharmacists are authorized to refuse to dispense a prescription if,
in their professional judgment, “potential adverse effects, interac-
tions or other therapeutic complications could endanger the
health of the patient.”75  This language suggests that the scope of a
pharmacist’s discretion is confined to the health and safety of the
patient.
Denial of over-the-counter emergency contraception based on
the pharmacist’s moral or religious beliefs is clearly beyond the au-
thorized scope of the profession, as such beliefs are not at all re-
MARC HELLER, CLAUDINA ASHELMAN-OWEN & COLLEEN SHAW AGAINST MATT WEAVER,
ANDREA BARCOMB & LISA MCGUINESS (Aug. 15, 2006), available at http://www.nyclu.
org/pdfs/rrp_ec_complaints_complaintletter_081506.pdf [hereinafter N.Y.C.L.U.
compl.].
68 Id. at 1.
69 OFFICE OF THE PROFESSIONS, N.Y. STATE EDUC. DEP’T, PROF’L. DISCIPLINE COM-
PLAINT FORM (Oct. 2006), http://www.op.nysed.gov/opd-complaint.pdf. See generally
Office of the Professions, N.Y. State Educ. Dep’t, http://www.op.nysed.gov/opd.htm
(last visited Apr. 28, 2008) (explaining New York’s professional discipline system and
listing e-mail and telephone contact information).  Complainants may also send an e-
mail to conduct@mail.nysed.gov.
70 N.Y. EDUC. LAW § 6511 (McKinney 2001).
71 Id. § 6509.
72 N.Y. COMP. CODES R. & REGS. tit. 8, § 29.2(a)(1) (2005).
73 N.Y. EDUC. LAW § 6511.
74 Id. § 6509(2).
75 N.Y. COMP. CODES R. & REGS. tit. 8, § 63.6(b)(8)(i)(e) (2003).
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lated to the health of the patient.76  Thus, pharmacists who refuse
to provide customers emergency contraception, without providing
immediate and realistic alternatives, are committing professional
misconduct and are subject to the sanctions prescribed by regula-
tion.  For example, the respondent pharmacists named in the
NYCLU complaint allegedly refused to honor the complaining pa-
tients’ refill prescriptions because women needing emergency con-
traception were “being irresponsible” and that obtaining
emergency contraception “should be inconvenient” for women.77
In doing so, the respondent pharmacists were substituting their
own subjective and judgmental opinions about the patient for that
which is authorized by law—professional judgment relating to the
patient’s health.  As the NYCLU argued, these types of assumptions
“are based on unjustified and unsupported judgments about the
women’s sexual behavior”78 and “impl[y] the view that women who
need [emergency contraception] deserve to get pregnant.”79
Pharmacists’ refusals of this type are inherently embedded
with these types of problematic assumptions about the customer’s
sexual “irresponsibility” or practices and as such are beyond the
authorized scope of the pharmacists’ practice.  Additionally, refus-
als based on sincerely held religious opposition to emergency con-
traception likely also amount to professional misconduct because
such opposition is not related to the health of the patient.  Accord-
ingly such pharmacist refusals likely constitute professional miscon-
duct under New York rules and regulations.
2. Patient Abandonment or Neglect
Committing unprofessional conduct as defined by state rules
or regulations is also grounds for sanctions prescribed by New York
Education Law § 6511.80  For example, it is professional miscon-
duct for a pharmacist to “abandon[ ] or neglect[ ] a patient or cli-
ent under and in need of immediate professional care, without
making reasonable arrangements for the continuation of such
care.”81 A guideline interpreting this provision provides that refus-
76 But see Stormans, 524 F. Supp. 2d at 1266 (granting preliminary injunction en-
joining regulation requiring pharmacists to dispense medications even if the pharma-
cist has a religious or moral reason to refuse to do so on the issue of free exercise of
religion).  For a more in-depth discussion of Stormans, see infra Part II.D.
77 N.Y.C.L.U. compl., supra note 67, at 6.
78 Id. at 9.
79 Id. at 10.
80 N.Y. EDUC. LAW § 6509(9) (McKinney 2001).
81 N.Y. COMP. CODES R. & REGS. tit. 8, § 29.2(1) (2005).
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ing to fill a prescription without providing a prompt referral consti-
tutes “abandonment and neglect” within the meaning of the
regulation.82  This guideline provides that “the pharmacist has a
professional obligation to take appropriate steps to avoid the possi-
bility of abandoning or neglecting a patient” when that pharmacist
recognizes a moral belief will pose a barrier to filling a patient’s
prescription.83  Thus a pharmacist’s morally based refusal to allow
a customer to purchase Plan B, without ensuring that another
pharmacist can provide the customer with Plan B as soon as possi-
ble, would likely constitute unprofessional conduct proscribed by
New York rules and regulations.
A customer who was denied emergency contraception, then,
could file a complaint with the Office of the Professions alleging
the pharmacist committed professional misconduct and aban-
doned or neglected a patient.  A customer may want to do this in
order to save the time and expense of litigation: filing a complaint
is simple and does not require an attorney.84  On the other hand,
the prospect of professional sanctions—which include suspension,
revocation, or annulment of the pharmacist’s license and fines85—
may not feel like an adequate remedy for a woman who has been
denied emergency contraception, as they may punish the refusing
pharmacist but do nothing to remedy the harm she personally
suffered.
B. Administrative Remedies
1. Unlawful Sex Discrimination in Public Accommodations
By New York regulation, it is illegal to discriminate on the ba-
sis of sex in a place of public accommodation.86  A pharmacy is
governed under these regulations as a place of public accommoda-
tion, as the statute governs “wholesale and retail stores and estab-
82 Memorandum from Lawrence H. Mokhiber, Executive Secretary, Pharmacy Bd.,
N.Y. State Office of the Professions, to Supervising Pharmacists Policy Guideline Con-
cerning Matters of Conscience (Nov. 18, 2005), http://www.op.nysed.gov/pharm
conscienceguideline.htm (last visited Mar. 3, 2008).
83 Id.
84 See supra note 69.
85 N.Y. EDUC. LAW § 6511.
86 N.Y. EXEC. LAW § 296(2)(a) (McKinney 2007).  “It shall be an unlawful discrimi-
natory practice for any person, being the owner, lessee, proprietor, manager, superin-
tendent, agent or employee of any place of public accommodation, resort or
amusement, because of the . . . sex . . . of any person, directly or indirectly, to refuse,
withhold from or deny to such person any of the accommodations, advantages, facili-
ties or privileges thereof . . . .” Id.
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lishments dealing with goods or services of any kind.”87  A woman
who was refused emergency contraception in a pharmacy could ar-
gue that such denial constitutes sex-based discrimination in a place
of public accommodation in violation of New York state law.88
The provisions of the state anti-discrimination law are en-
forced through the New York State Division of Human Rights
(“DHR”).  To file a complaint with the DHR, the aggrieved person
must submit a complaint which indicates the name and address of
the person alleged to have committed the unlawful discriminatory
practice complained of and describing the discriminatory prac-
tice.89  The agency then has 180 days to determine whether there is
probable cause to believe that the respondent engaged in unlawful
discriminatory practice.90  If the probable cause standard is met,
the respondent will then be required to report to a hearing con-
ducted by the DHR.91  After the hearing, the DHR commissioner
has 180 days to determine whether the respondent committed the
alleged unlawful discrimination.92  The statute also prescribes a
one-year statute of limitations.93  Complainants may obtain judicial
review of agency orders, including cease and desist orders, orders
awarding damages, and orders dismissing complaints.94
New York courts also have jurisdiction to hear claims of unlaw-
ful discrimination.95  However, once a complainant elects the ad-
ministrative forum by filing a complaint with the DHR, a judicial
action on the same complaint is generally barred.96  There are
87 N.Y. EXEC. LAW § 292(9).
88 See N.Y.C.L.U. compl., supra note 67, at 13.  In their complaint, the NYCLU
alleged that refusal to honor refills of emergency contraception prescriptions consti-
tutes sex discrimination because only women use emergency contraception.  The
NYCLU further analogized refusal to honor refill prescriptions of emergency contra-
ception to refusal to provide insurance coverage for contraception, which some
courts have found violates federal law under Title VII. Id. at 13–14.
89 N.Y. EXEC. LAW § 297(1); see also N.Y. COMP. CODE R. & REGS. tit. 9, § 465.3(c)
(2007).
90 N.Y. EXEC. LAW § 297(2)(a).
91 Id. § 297(4)(a).
92 Id. § 297(4)(a).
93 Id. § 297(5).
94 Id. § 298.
95 Id. § 297(9).  The private cause of action based on sex discrimination is dis-
cussed in Section IV, infra.
96 Id. § 297(9); see also Johnson v. County of Nassau, 411 F. Supp. 2d 171, 184
(E.D.N.Y. 2006) (holding that court lacked subject matter jurisdiction over plaintiff’s
discrimination claim because plaintiff chose to have his claim adjudicated by the
DHR); State Div. of Human Rights v. Luppino, 35 A.D.2d 107 (N.Y. App. Div. 1970)
(New York legislature intended, by giving individuals a choice between suing in court
or seeking administrative relief, to limit persons to out-of-pocket damages when they
elect the administrative remedy).
2008] A PLAN C FOR PLAN B 419
three exceptions to this rule: the election of remedies rule does
not apply where the division dismissed a complaint on the grounds
of administrative convenience, on the grounds of untimeliness, or
on the grounds that the election of remedies is annulled.97
In order to have standing to file a complaint alleging unlawful
discrimination, the complainant must be an “aggrieved person”
within the meaning of the statute.98  Courts have interpreted the
statute’s “aggrieved person” to mean “[an] individual who is the
alleged victim of the alleged discriminatory practice.”99  Addition-
ally, organizations have institutional standing to file a complaint so
long as the complainant is a “bona fide recognized organization
representing that class with a specific interest in the litigation in
question.”100
In making the initial determination whether to proceed with a
hearing, the DHR must determine whether there is probable cause
to believe the alleged discriminatory practice occurred.101  A “ra-
tional basis” for sustaining the complaint is sufficient in order to
satisfy this probable cause standard.102  If there is no probable
cause to believe that the respondent has engaged in unlawful dis-
criminatory practice, the DHR is authorized to dismiss the
complaint.103
If the commissioner finds that the respondent engaged in un-
lawful discriminatory practice, she retains broad discretionary pow-
ers to grant relief “reasonably related to the discriminatory
conduct.”104  The commissioner is authorized to issue a cease and
desist order, award compensatory damages, and require a compli-
97 N.Y. EXEC. LAW § 297(9).
98 Id.
99 Weinstein v. Hosp. for Joint Diseases and Med. Ctr., 81 Misc.2d 366, 368 (Sup.
Ct. Westchester Co. 1975) (holding that wife of person who was discriminated against
is not an “aggrieved person” within the meaning of the statute).
100 Nat’l Org. of Women v. State Div. of Human Rights, 34 N.Y.2d 416, 420 (1974);
see also N.Y. COMP. CODE RULES & REGS. tit. 9, § 465.3(a)(1).  In Nat’l Org. of Women,
the complainant had institutional standing to challenge publisher of newspaper when
the classified section contained separate “male” and “female” sections as “a bona fide
and nationally recognized organization dedicated to eliminating discriminatory prac-
tices against women.” Id. at 419–20.
101 N.Y. EXEC. LAW § 297(2)(a).
102 State Div. of Human Rights v. N.Y. State Drug Abuse Control Comm’n, 399
N.Y.S.2d 541, 543 (N.Y. App. Div. 1977); see also Mendoza v. State Div. of Human
Rights, 424 N.Y.S.2d 447, 448 (N.Y. App. Div. 1980) (remanding proceeding to the
DHR because “[t]he inaccuracy and impreciseness in presentation of important evi-
dence in the record resulted in a determination lacking the rational basis” required
for dismissing a complaint pursuant to N.Y. EXEC. LAW § 297(2)).
103 N.Y. EXEC. LAW § 297(2)(a).
104 N.Y. City Transit Auth. v. State Div. of Human Rights, 78 N.Y.2d 207, 217 (1991).
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ance report.105  The courts’ recognition of the broad discretion of
the commissioner accords with “the extremely strong statutory pol-
icy of eliminating discrimination” and reflects the notion that a
statutory remedy “involves a vindication of both the individual’s in-
terests and those of society.”106
A woman over the age of eighteen who is denied emergency
contraception by a pharmacist who wishes to elect an administra-
tive, rather than a judicial, remedy could file a complaint with the
DHR alleging unlawful sex discrimination.  Additionally, reproduc-
tive rights organizations are authorized to file complaints on behalf
of women affected by this type of discriminatory conduct.107
Electing the administrative remedy may make sense for a wo-
man who wishes to avoid investing the time and expense required
for a lawsuit, while allowing her to assert that the refusing pharma-
cist’s conduct was unlawful and discriminatory.  An affected woman
would not need to hire an attorney or pay any court fees in order
to file a sex discrimination complaint with the DHR.  Additionally,
this administrative remedy authorizes the DHR to award money
damages, which may be more adequate relief, or feel like more
“personal” relief, than the professional sanctions authorized when
the complainant alleges professional misconduct.  Electing the ad-
ministrative remedy can be a frustratingly slow process—an ag-
grieved woman could wait almost a year to hear whether the
agency agrees that the pharmacist committed unlawful discrimina-
tion108—but may still be the fastest option for the woman.
105 N.Y. EXEC. LAW §§ 297(4)(a)(i), (iii), and (vii).
106 N.Y. City Transit Auth., 78 N.Y.2d at 216; see also Freudenthal v. County of Nas-
sau, 99 N.Y.2d 285, 291 (2003) (“[T]he Division is empowered to make an aggrieved
party whole and, in the process, to eradicate the underlying discriminatory practices
that resulted in injury.”).
107 Nat’l Org. of Women v. State Div. of Human Rights, 34 N.Y.2d 416, 420 (1974).
108 N.Y. EXEC. LAW § 297(2)(a) (“Within one hundred eighty days after a complaint
is filed, the division shall determine whether it has jurisdiction and, if so, whether
there is probable cause to believe that the person named in the complaint, hereinaf-
ter referred to as the respondent, has engaged or is engaging in an unlawful discrimi-
natory practice.”); N.Y. EXEC. LAW § 297(4)(a) (“Within two hundred seventy days
after a complaint is filed . . . the division shall cause to be issued and served a written
notice, together with a copy of such complaint, as the same may have been amended,
requiring the respondent or respondents to answer the charges of such complaint
and appear at a public hearing before a hearing examiner at a time not less than five
nor more than fifteen days after such service and at a place to be fixed by the division
and specified in such notice.”).
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C. Private Causes of Action
1. Unlawful sex discrimination in public accommodations
A woman denied emergency contraception may, instead of
electing the administrative remedy and filing a sex discrimination
complaint with DHR, elect a judicial remedy.109  The statutory
scheme authorizes New York courts to exercise jurisdiction over a
cause of action claiming unlawful discriminatory practice, so long
as the plaintiff did not also file a complaint with the DHR.110  Al-
though there is very little case law that addresses gender-based dis-
crimination in public accommodations, the case law addressing
other protected classes is instructive.
The burden is on the plaintiff to make a prima facie showing
of discrimination.111  The cases suggest that this burden is met if
the plaintiff establishes that she was subjected to unequal treat-
ment because of her membership in a class protected by New York
Human Rights Law.112  Gender is a protected class under this body
of law.113  New York and federal constitutional precedent “estab-
lish[ ] that gender discrimination occurs when men and women
are not treated equally and one gender is benefited or burdened as
opposed to the other.”114
After the plaintiff makes her prima facie showing of unlawful
discrimination, the burden then shifts to the defendant to show a
“legitimate, non-discriminatory reason for the difference in treat-
ment.”115  In the context of health care, disparate treatment based
109 Id. § 297(9).
110 Id.
111 North Shore Univ. Hosp. v. Rosa, 86 N.Y.2d 413, 419 (1995).
112 See, e.g., Elaine W. v. Joint Diseases North General Hospital, Inc., 81 N.Y. 2d 211,
216 (1993) (recognizing the court had consistently held “distinctions based solely
upon a woman’s pregnant condition constitute sexual discrimination” under New
York Human Rights Law protecting sex discrimination in public accommodations).
See also U.S. Power Squadrons v. State Human Rights Appeal Bd., 59 N.Y.2d 401, 413
(1983).  In U.S. Power Squadrons, the DHR found that respondent corporation’s blan-
ket refusal to extend membership to female applicants who are otherwise qualified
constituted unlawful sex discrimination. Id. at 407.  The court affirmed the agency’s
finding, noting that “membership in petitioner is extended to all males who pass the
basic piloting course, the actual and potential membership is more public than pri-
vate and there is no plan or purpose of exclusivity other than sexual discrimination.”
Id. at 413.
113 N.Y. EXEC. LAW § 291(2) (McKinney 2007) (“The opportunity to . . . the use of
places of public accommodation . . . without discrimination because of . . . sex . . . is
hereby recognized as and declared to be a civil right.”).
114 Hernandez v. Robles, 7 N.Y.3d 338, 375 (2006).
115 North Shore Univ. Hosp., 86 N.Y.2d at 419; see also Cahill v. Rosa, 89 N.Y.2d 14, 25
(1996) (citing Laverack & Haines, Inc. v. N.Y. State Div. of Human Rights, 88 N.Y.2d
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on medical necessity meets this standard.116  In Cahill v. Rosa, the
plaintiffs alleged that defendants violated public accommodations
law when they refused to treat patients who were known or sus-
pected to be HIV-positive.117  There, the court held that a medical
provider has an ability to refer patients elsewhere for treatment so
long as they have a legitimate, non-discriminatory reason for doing
so.118  The medical provider in Cahill did not satisfy this stan-
dard.119  Similarly, in North Shore University Hospital v. Rosa, the
plaintiffs alleged that New York Public Accommodations Law was
violated when defendant medical facility used heightened precau-
tionary measures when it treated a patient it suspected had
AIDS.120  There, the court found that defendant’s “strict isolation
technique” under its infectious disease protocol was supported by
medical justification and therefore constituted a “legitimate, non-
discriminatory reason” for the difference in treatment.121  If the
presumption of discrimination is rebutted, the burden shifts back
to the plaintiff to establish that the reasons proffered were not the
true reasons, but were a pretext for discrimination.122
The court’s rationale in Elaine W. v. Joint Diseases North General
Hospital123 is instructive in considering discrimination principles in
the context of access to emergency contraception.  In Elaine W.,
the plaintiffs instituted an unlawful sex discrimination action alleg-
ing that defendant hospital’s refusal to admit pregnant women into
734, 736 (1996) (finding a legitimate, non-discriminatory explanation in age discrimi-
nation suit when plaintiff was terminated due to “business setbacks”).
116 Cahill, 89 N.Y.2d at 25; see also North Shore Univ. Hosp., 86 N.Y.2d at 419–20 (cit-
ing Elaine W. v. Joint Diseases N. Gen. Hosp., Inc., 81 N.Y.2d 211, 217 (1993)).
117 89 N.Y.2d at 18.
118 Id. at 24.
119 See id.
120 North Shore Univ. Hosp., 86 N.Y.2d at 416.
121 Id. at 419.
North Shore [met their burden of demonstrating a legitimate reason
for the difference in treatment] by showing that at the relevant time, its
protocol was reasonable, medically warranted and consistent with its de-
sire to protect patients and staff from the spread of infectious dis-
eases. . . . Clearly, respondent’s disease protocol was consistent with
accepted medical practice in 1985 for treatment of patients known or
perceived to be at high risk of infection of the then recently discovered,
contagious and fatal disease and not a pretext for discrimination.
Id. at 419–20.
122 Id. at 419–20; see also Johnson v. Lord & Taylor, 807 N.Y.S.2d 367, 367 (N.Y. App.
Div. 2006) (no unlawful racial discrimination when defendant articulated a legiti-
mate, non-discriminatory purpose and plaintiff did not allege any competent evi-
dence that defendant’s nondiscriminatory explanation of the event was a pretext for
racial discrimination).
123 81 N.Y.2d 211 (1993).
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its drug detoxification program violated New York State Human
Rights Law.124  The court first noted that, in interpreting anti-sex-
discrimination law, New York courts have consistently held that
“distinctions based solely upon a woman’s pregnant condition con-
stitute sexual discrimination.”125  The court rejected the defen-
dant’s argument that the disparate treatment was justified on
medical grounds.126  The defendant claimed that “North General
excludes pregnant women because it believes it lacks the equip-
ment to treat them safely, it has no obstetricians on its staff and it is
not licensed to render obstetrical care.”127  In rejecting this as a
legitimate medical justification, the court noted that the burden
rests on the actor drawing distinctions based upon pregnancy to
prove that those “distinctions are based upon medical necessity,
not upon generalizations associated with pregnant women.”128
The court then held that the challenged policy constituted facial
sex discrimination.129
Refusal to provide emergency contraception constitutes sex
discrimination under the reasoning of Elaine W.  First, only women
use emergency contraception; a pharmacist’s refusal to provide it
results in “less comprehensive benefits being offered to women
than those offered to men.  Because only women use [emergency
contraception], only women are refused prescriptions or refills
based on pharmacists’ non-health related judgments regarding
their sexual practices.”130
Second, there is no medical justification for the disparate
treatment.  Because of the drug’s medically proven safety, there is
no valid medical justification for refusing to provide emergency
contraception.131  The court in Elaine W. explicitly rejected pater-
nalistic or “well-intentioned” reasons to support a medical justifica-
tion: “Many discriminatory practices develop improperly because
of a paternalistic sense of what is ‘best’ for those who are discrimi-
nated against . . . .  If there is no medical basis for the discrimina-
tion, the fact that it was undertaken with good intentions is
124 Id. at 215.
125 Id. at 216 (citations omitted).
126 Id. at 215.
127 Id.
128 Id. at 217.
129 Id. at 216.
130 N.Y.C.L.U. compl., supra note 67, at 14.
131 See, e.g., Weismiller, supra note 14, at 710 (no medical contraindications associ-
ated with emergency contraceptive use); Grimes & Raymond, supra note 14, at 183
(noting that emergency contraception is “very safe”).
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irrelevant.”132  Absent a medical justification, a pharmacist’s refusal
to dispense emergency contraception based on moral or religious
reasons is based on the same sexist, paternalistic, or simply non-
medical notions that the court found unacceptable in Elaine W.
There are obvious drawbacks to commencing a civil action
against a refusing pharmacist: litigation is expensive and time-con-
suming.  Litigation may simply not be an option for many women
affected by a refusing pharmacist.  However, reproductive rights or-
ganizations may wish to develop projects whose purpose is to
gather information and engage in litigation of this nature.  This
would alleviate the burden of expense on the plaintiff while simul-
taneously setting crucial local or state precedent.
2. Breach of Fiduciary Duty
A complaint filed in civil court alleging sex discrimination
could also include a breach of fiduciary duty cause of action.  Re-
fusing to provide emergency contraception over-the-counter is
likely a breach of the fiduciary relationship between the pharmacist
and the customer.  A New York state court explicitly held that a
fiduciary relationship exists between a pharmacist and customer in
Anonymous v. CVS Corp.133  In reaching its conclusion that the phar-
macist–customer relationship can correctly be characterized as a
fiduciary relationship, the court in CVS also noted that pharmacists
“do more than dispense a product.  They are responsible for col-
lecting otherwise confidential medical information, and providing
drug advice to customers.”134  New York state courts have also de-
fined the applicable standard of care for pharmacists, finding that
they must exercise “the highest practicable degree of prudence,
thoughtfulness and vigilance commensurate with the dangers in-
volved and the consequences which may attend inattention.”135
Failure to provide emergency contraception to a customer
who shows proof of age is a breach of the pharmacist’s duty to the
customer.  The reasoning of pharmacists who deny emergency con-
traception to women who request it is not based on any objective
medical condition of the customer; rather, such reasoning is based
on sexist and paternalistic assumptions about her, or is based on
132 Elaine W., 81 N.Y.2d at 217–18.
133 728 N.Y.S.2d 333, 338 (N.Y. Sup. Ct. 2001) (finding that the principal character-
istics of a fiduciary relationship, dependency and influence, are present in the trans-
action between pharmacist and customer).
134 Id. at 337.
135 Hand v. Krakowski, 453 N.Y.S.2d 121, 122 (N.Y. App. Div. 1982); see also France
v. State, 506 N.Y.S.2d 254, 255 (N.Y. Ct. Cl. 1986).
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non-medical religious motivations.136  The FDA’s Center for Drug
Evaluation and Research’s conclusion that “the available scientific
data are sufficient to support the safe use of Plan B as an over the
counter product, but only for women who are [seventeen] years of
age and older”137 indicates that, in the context of the pharmacist’s
duty of care, any “dangers involved” only apply to the age of the
customer.  Because the FDA has deemed emergency contraception
to be safe and legal for women over the age of eighteen, the only
duty the pharmacist owes to a customer requesting Plan B is to
verify her age.  Virtually any other determinations made by the
pharmacist beyond age verification would be non-medical, because
the FDA has explicitly approved emergency contraception’s safety
for women over the age of eighteen, without restrictions on fre-
quency of use.  The pharmacist’s injection of his or her moral or
religious beliefs, or assumptions about the customer’s marital sta-
tus or sexual proclivities, should have nothing to do with the phar-
macist’s obligation to exercise “the highest practicable degree of
prudence, thoughtfulness and vigilance commensurate with the
dangers involved . . . .”138
3. Wrongful Conception Tort
A woman who became pregnant or had an abortion as a result
of a pharmacist’s refusal to provide emergency contraception may
be able to sue the pharmacist on the tort theory of wrongful con-
ception.  New York courts recognize the tort of wrongful concep-
tion when a medical professional’s negligence results in the birth
of a healthy child;139 however, the courts have so far not explicitly
extended the wrongful conception tort to the context of failure to
provide emergency contraception.
The New York Court of Appeals has implicitly indicated that
the tort of wrongful conception is a viable cause of action when a
physician or other medical professional’s negligence causes an un-
wanted pregnancy that results in an otherwise healthy child.140  Ad-
136 See Page, supra note 7, at 105–19 (discussing scientific studies on the safety and
effectiveness of Plan B and reviewing the pro-lifers responses).
137 Lester B. Crawford, Comm’r, Fed. Drug Admin., FDA Takes Action on Plan B
(Aug. 26, 2005), available at http://www.fda.gov/bbs/topics/NEWS/2005/NEW
01223.htm.
138 Hand, 453 N.Y.S.2d at 122.
139 See O’Toole v. Greenberg, 477 N.E.2d 445 (N.Y. 1985).
140 Id. at 447.  The issue in O’Toole was whether plaintiffs, in a medical malpractice
action, could receive damages for the ordinary costs of raising a normal, healthy child
after a negligently performed tubal ligation procedure. Id. at 446.  The court noted
that the other branch of plaintiff’s cause of action seeking damages for expenses in-
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ditionally, four departments in the Appellate Division have held
that a cause of action for medical malpractice when the physician’s
negligence results in the birth of a normal child states a legally
cognizable claim.141  After an exhaustive review of the ways in
which other jurisdictions have dealt with the wrongful conception
tort, the court in Weintraub v. Brown concluded “there is wide-
spread agreement among the several jurisdictions that have consid-
ered the issue that complaints alleging wrongful conception state a
valid cause of action.”142
Many wrongful conception cases have been brought as a result
of a negligently performed sterilization procedure.  In Miller v. Ri-
vard, the court recognized a wrongful conception cause of action
when the defendant physician negligently performed a vasec-
tomy.143  In Ziemba v. Sternberg,144 the court held a legally cogniza-
ble wrongful conception cause of action was stated when the
defendant negligently failed to diagnose the plaintiff’s preg-
nancy.145  And in O’Toole v. Greenberg, defendants conceded that
plaintiffs stated a legally cognizable wrongful conception cause of
action for emotional damages and medical expenses associated
with the pregnancy that resulted from a negligently performed
tubal ligation.146  Additionally, in Miller, the Appellate Division
noted in dicta that New York courts recognize a pharmacist’s negli-
gent filling of a prescription for contraception can be the basis of a
wrongful conception cause of action.147
The court in Ziemba suggested there are two requirements to
sufficiently state a wrongful conception cause of action: the defen-
dant breached the applicable standard of care, and the defendant’s
curred for the pregnancy, delivery, and postpartum care rendered to plaintiff and her
child was not at issue. Id.
141 Weintraub v. Brown, 470 N.Y.S.2d 634, 637 (N.Y. App. Div. 1983).
142 Id.
143 Miller v. Rivard, 585 N.Y.S.2d 523, 526 (N.Y. App. Div. 1992).
144 Ziemba v. Sternberg, 357 N.Y.S.2d 265, 267 (N.Y. App. Div. 1974).
145 Id. at 269; see also Sala v. Tomlinson, 422 N.Y.S.2d 506 (N.Y. App. Div. 1979)
(action brought against physician for negligently performed sterilization operation).
146 477 N.E.2d at 446 n.2 (1985).  The court noted that plaintiff’s second cause of
action—“based upon allegations of medical malpractice and [seeking] damages for
physical and emotional injuries resulting from labor and delivery and the necessity of
a second sterilization procedure”—was also not at issue on appeal, because defend-
ants had conceded. Id.
147 Miller, 585 N.Y.S.2d at 524 (“The gravamen of their suit is what courts and com-
mentators have come to call ‘wrongful conception’ or ‘wrongful pregnancy’, i.e., the
negligent performance of a sterilization or abortion procedure by a physician, or the
negligent filling of a contraceptive prescription by a pharmacist, as a result of which
the plaintiffs conceived and became the parents of a healthy but unwanted child.”
(citation omitted)).
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negligence resulted in an unintended pregnancy.148  The pharma-
cist owes an adult patient “the highest practicable degree of pru-
dence, thoughtfulness and vigilance commensurate with the
dangers involved and the consequences which may attend inatten-
tion.”149  And, because the FDA has deemed emergency contracep-
tion to be safe and legal for women over the age of eighteen, the
only duty the pharmacist owes to a patient requesting Plan B is to
verify that she is in fact eighteen years of age.  The pharmacist’s
infusion of her moral beliefs into the Plan B transaction is an in-
trinsically non-medical determination.  Because the FDA has ex-
plicitly approved emergency contraception’s safety for women over
the age of eighteen, without restrictions on frequency of use, any
other inquiry falls outside the duty of care the pharmacist owes the
patient.
In terms of damages recoverable, the court in O’Toole explicitly
held that plaintiffs in a wrongful conception suit may not seek
damages for the ordinary costs of raising a healthy, normal
child.150  The court found that “the birth of a healthy child, as but
one consequence of defendant’s tortious conduct, does not consti-
tute a harm cognizable at law.”151  The court also based its holding
on public policy, stating that “[t]o hold that the birth of a healthy
child represents a legal harm would be to engage this court in the
jurisprudentially improper task of recasting the immutable, intrin-
sic value of human life according to the financial burden thus im-
posed upon the parents.”152
In Weintraub, the court indicated that New York adopts the ap-
proach espoused by a majority of other jurisdictions that have con-
sidered the wrongful conception cause of action, which is to award
damages for medical expenses incurred during the pregnancy, but
not for costs associated with raising the child.153  The Weintraub
148 Ziemba, 357 N.Y.S.2d at 269.  The Ziemba court stated:
When, as here, it is asserted that, as one of the consequences of defen-
dant physician’s lack of reasonable care, plaintiff was not advised of her
pregnancy so that she could terminate it within a reasonable time, as
she was entitled to do, and was advised by another physician when the
pregnancy was discovered by him as to the danger involved in an abor-
tion at that time, we believe the damages subsequently sustained by her
and her husband may be the natural consequences of defendant’s mal-
practice for which recovery will lie.
Id.
149 Hand v. Krakowski, 453 N.Y.S.2d 121, 122 (N.Y. App. Div. 1982).
150 O’Toole, 477 N.E.2d at 446.
151 Id. at 448.
152 Id.
153 Weintraub v. Brown, 470 N.Y.S.2d 634, 641 (N.Y. App. Div. 1983).
428 NEW YORK CITY LAW REVIEW [Vol. 11:401
court concluded that “[t]here . . . is general agreement that the
plaintiffs in a wrongful conception action may recover from the
tort-feasor for the expenses of the unsuccessful sterilization proce-
dure, the pain and suffering associated with the pregnancy, the
costs of delivery, lost wages, and loss of consortium.”154  The Wein-
traub court then noted that the majority of jurisdictions deny recov-
ery of child-rearing costs for public policy reasons, to protect the
child, and because calculating these damages would be unduly
speculative.155
The biggest obstacle the wrongful conception avenue of relief
poses to a customer denied emergency contraception is finding a
pregnant plaintiff who either has chosen to have the unwanted
child or is willing to seek the cost of an abortion procedure as dam-
ages.156  Thus, for privacy reasons, women may be reluctant to insti-
tute a wrongful conception suit.  Additionally, complicated policy
issues surrounding the notion of ascribing monetary value as dam-
ages associated with an unwanted child arise in the context of a
wrongful conception claim.157  For similar reasons discussed by the
Weintraub court to support the bar on recovering costs associated
with rearing a healthy child—that the courts should not adjudicate
the birth of a healthy child as a legally cognizable “injury”158—a
woman denied emergency contraception may be reluctant to seek
damages for pregnancy-related costs.
On the other hand, the wrongful conception cause of action—
which does not characterize the actual birth of an unwanted child
as a legally compensable injury—could be viewed as a practical
method of obtaining relief for expenses incurred as a result of a
pharmacist’s refusal to provide emergency contraception.  One
theory, which supports recovery under a wrongful conception
claim, views “the lost parental opportunity to avoid conception or
terminate a pregnancy as the legally cognizant injury, rather than
expressly framing the child’s life itself as the injury.”159 Thus, by
154 Id. at 638 (citation omitted).
155 Id. at 638–41.
156 “The right to have an abortion may not be automatically converted to an obliga-
tion to have one.” Ziemba v. Sternberg, 357 N.Y.S.2d 265, 269 (N.Y. App. Div. 1974).
Also, it is not unreasonable to conclude that a court should award abortion costs,
since such costs do not carry the same policy concerns as do the costs of raising a
healthy child.
157 Kathleen A. Mahoney, Malpractice Claims Resulting from Negligent Preconception Ge-
netic Testing: Do These Present a Strain of Wrongful Birth or Wrongful Conception, and Does
the Categorization Even Matter?, 39 SUFFOLK U. L. REV. 773, 778 (2006).
158 Weintraub, 470 N.Y.S.2d at 641.
159 Mahoney, supra note 157, at 780.
2008] A PLAN C FOR PLAN B 429
refusing to award damages for the cost of raising a healthy but un-
wanted child, as New York does, the legally compensable harm is
characterized as the mother’s experience, not the child’s life.160
D. Pharmacist Refusals and the First Amendment: The Impact of
Stormans
In light of the court’s decision in Stormans, Inc. v. Selecky,161 the
private causes of action described above may become an increas-
ingly useful tool for women denied emergency contraception by
pharmacists.  In Stormans, the plaintiffs are two pharmacists whose
religious beliefs informed their view that life begins at conception,
and who “claim a right of conscience to refuse to dispense Plan B,
and to instead refer the patient to a nearby pharmacy that will dis-
pense the drug.”162  Plaintiffs challenged Washington state regula-
tions which provided, in part, that:
Pharmacies have a duty to deliver lawfully prescribed drugs or
devices to patients and to distribute drugs and devices approved
by the U.S. Food and Drug Administration for restricted distri-
bution by pharmacies, or provide a therapeutically equivalent
drug or device in a timely manner consistent with reasonable
expectations for filling the prescription.163
The Washington State Board of Pharmacy acknowledged that the
regulations reflected a desire to provide definitive standards for
pharmacists in situations where the pharmacist’s moral beliefs were
at odds with a patient’s request for legally prescribed medica-
tions.164  Accordingly, the Board concluded that the regulation
prohibits a pharmacy from implementing a policy in which a phar-
macist is permitted to refer a patient to another pharmacy to avoid
filling a prescription the pharmacist objects to due to moral or eth-
ical reasons.165
Plaintiffs argued that the challenged regulations violate the
Free Exercise Clause of the First Amendment.166  Under that
clause, the government “may not enact laws that suppress religious
160 Wendy F. Hensel, The Disabling Impact of Wrongful Birth and Wrongful Life Actions,
40 HARV. C.R.-C.L. L. REV. 141, 151 (2005).
161 524 F. Supp. 2d 1245 (W.D. Wash. 2007).
162 Id. at 1248–49.
163 Id. at 1252 (quoting WASH. ADMIN. CODE 246-869-010 (2007)).
164 Id. at 1253 (internal references omitted).
165 Id.
166 Id. at 1256.  Plaintiffs asserted other constitutional claims, but the court de-
clined to reach them in granting the preliminary injunction based on plaintiffs’ First
Amendment claim. Id. at 1266.
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belief or practice.”167  Courts apply strict scrutiny to laws which
facially discriminate against individuals because of their religious
beliefs.168  On the other hand, laws of general applicability—laws
which are facially neutral with respect to religion—do not require
a compelling governmental interest, “even if the law has the inci-
dental effect of burdening a particular practice.”169
In its First Amendment analysis, the court first determined
whether the challenged regulations were facially neutral.170  While
the court determined that the challenged regulations were facially
neutral,171 the court ruled that the “evolution of the regulations”
demonstrated that they in fact targeted the religious practices of
certain citizens and therefore could not be considered neutral.172
In turning to the general applicability analysis, the court ruled that
the regulations were not of general applicability because they un-
constitutionally targeted religious practice.173  Thus, the court sub-
jected the challenged regulations to strict scrutiny “[b]ecause the
regulations appear to intentionally place a significant burden on
the free exercise of religion for those who believe life begins at
conception.”174
The court then determined whether the regulations withstood
the requisite strict scrutiny analysis.  The defendants argued that
two government interests support the constitutionality of the regu-
lations.  The first was promoting public health by ensuring timely
access to Plan B.175  The second asserted government interest was
preventing sex discrimination.176  The court ruled that “the inter-
ests promoted by the regulations have more to do with convenience and
heartfelt feelings than with actual access to certain medications.”177
In rejecting defendants’ first argument, the court noted that:
While it is obviously conceivable that a patient in need of Plan B
could ultimately be denied access to the drug during its time of
effectiveness, that eventuality is just as likely to occur for reasons
that are wholly acceptable under the regulations: lack of money,
167 Id. at 1257; see also U.S. CONST. amend. I.
168 524 F. Supp. 2d at 1254.
169 Id. (citing Employment Div., Dept. of Human Res. of Or. v. Smith, 494 U.S. 872
(1990)).
170 Id. at 1257–60.
171 Id. at 1258.
172 Id. at 1260.




177 Id. (emphasis added).
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the drug is not in stock, no one has previously requested it, or
the store is closed on Sunday. In short, lack of access to Plan B
has thus far not been demonstrated, and the concerns that have
been expressed about availability are not compelling.178
The court also rejected defendants’ sex discrimination argument,
remarking that “[t]he United States Supreme Court has recog-
nized that reasonable people disagree over when life begins, and
the refusal to participate in an act that one believes terminates a
life has nothing to do with gender or gender discrimination.”179
Remarkably, the court noted that “[t]he plaintiffs’ objection to
Plan B is not about gender, it is about the sanctity of life as defined
by their religious teachings.”180  Accordingly, the court granted the
preliminary injunction with respect to the plaintiffs’ First Amend-
ment claim.181
In light of Stormans, state measures enacted to ensure women
have timely access to emergency contraception may be threatened.
The First Amendment implications of consumer-protective state
measures, such as those enacted by the Washington State Board of
Pharmacy—particularly under the court’s reasoning in Stormans, in
which pharmacist refusals have “nothing to do with gender”182 and
access to Plan B is characterized as a matter of “convenience”183—
endanger the constitutionality of such measures.  Advocates should
consider focusing on the private causes of action discussed in this
section in determining the most viable place to continue fighting
for access to emergency contraception.
III. A PLAN C FOR YOUNG WOMEN
The way in which the behind-the-counter rule permits phar-
macist refusals is not the only objectionable aspect of the rule—the
age restriction, too, must be analyzed from a feminist perspective.
The FDA rule’s age restriction is a prime example of what
Buchanan has described as “[t]he state impos[ing] quasi-parental
control over young women’s sexuality.”184  Because “[m]ost adoles-
178 Id.
179 Id. (citing Bray v. Alexandria Women’s Health Clinic, 506 U.S. 263, 271–74
(1993)).
180 Id. at 1264.  The way in which the court is able to remove gender from its analy-
sis is quite remarkable and is reflective of MacKinnon’s argument that “women, be-
cause of their sex, are subjected to social inequality at each step in the process of
procreation.”  MacKinnon, supra note 50, at 1309.
181 524 F. Supp. 2d at 1266.
182 Id. at 1263.
183 Id.
184 Buchanan, supra note 8, at 1255 (italics omitted).
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cents depend substantially on the public sector to help support
their healthy sexual development and to protect them from sexual
violence, disease, and pregnancy,”185 a critique of the rule’s age
restriction is critical.  First, the age restriction was unsupported by
any medical or scientific justification, which would indicate Plan B
is less safe for adolescent users.186  Second, it has “enormous conse-
quences”187 for young women who may not have health insurance,
transportation to a clinic, or time to make an appointment within
the recommended seventy-two hour period of time between unpro-
tected intercourse and taking Plan B.188  The restriction on young
women’s access to Plan B without a prescription supports the argu-
ment that:
[C]ontemporary public policies on adolescent sexuality are be-
ing designed in ways that significantly limit young women’s ac-
cess to information and health care regarding sexual behaviors
and sexual desire; diminish the supports available to young wo-
men . . . ; limit the professional license of educators and health
workers who typically support teens in their sexual and repro-
ductive decision making; and circumscribe the options available
to young women who experience sexual desire or sexual vio-
lence in the name of protecting the young.189
Thus, because of the barriers young women face in accessing
reproductive services, coupled with the lack of medical justification
for the age restriction, “it is critical to examine the ways in which
public policies concerning young women’s sexualities have been
185 Michelle Fine & Sara I. McClelland, The Politics of Teen Women’s Sexuality: Public
Policy and the Adolescent Female Body, 56 EMORY L.J. 993, 995 (2007).
186 See G.A.O. REPORT, supra note 34, at 31 (“There were no safety issues that would
require age-related restrictions that were identified with the original [new drug appli-
cation] for prescription Plan B. FDA approved this application upon determining that
Plan B met the statutory standards of safety and effectiveness, manufacturing and con-
trols, and labeling.”); see also Brief of Plaintiffs, supra note 4, at 37 (“Dr. Beitz, Acting
Director of the Office of Drug Evaluation III, reiterated her view that no age restric-
tion was appropriate ‘[i]n the absence of new data to support’ such a restriction.  Dr.
Ganley, Director of the FDA’s Office of Nonprescription Products, likewise stated
‘[n]o new data was provided to suggest the restriction based on age is necessary.’ Dr.
Jenkins, Director of the Office of New Drugs, similarly reiterated his prior position
adding, ‘I am not aware of any new data that supports the need for an age restriction.’
”) (citations omitted).
187 Fine & McClelland, supra note 185, at 1016.
188 Id.  (“Young women must access medical care, get a prescription from a physi-
cian, and find a pharmacist who is willing to fill the prescription—all within the sev-
enty-two hour window that emergency contraception needs to be taken in order to be
effective. These obstacles represent serious constrictions on the reproductive freedom
of those young women who have considerably less access to medical care, physicians,
and pharmacies.”).
189 Id. at 995 (format altered).
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forged within religious and ‘moralizing’ discourses.”190  This Part
will briefly discuss Carey v. Population Services International,191 in
which the United States Supreme Court laid the constitutional
groundwork for minors’ right to access contraceptives.  This Part
will next discuss the relevance of Carey in light of the challenge to
the behind-the-counter restriction brought in Tummino v. von Es-
chenbach.192  Lastly, this Part will employ a feminist theoretical per-
spective to support the argument against the age restriction,
focusing on the way in which the responsibility and “shame” of sex-
ual activity falls squarely and solely on the shoulders of young wo-
men while simultaneously assuming that men eighteen or older,
who are under no circumstances approved as users of Plan B, are
more qualified to make the decision to purchase the drug.
A. The Carey Backdrop
In Carey, the plaintiffs challenged a statute that criminalized
the sale or distribution of a contraceptive to adolescents under the
age of sixteen and required that distributors of contraceptives to
those over the age of sixteen be licensed pharmacists.193  Signifi-
cantly, the Court affirmed the existence of a constitutionally pro-
tected right to decisional privacy, in certain important personal
matters.194  Thus, the Constitution affords protection for individu-
als to make private decisions about contraception.195
The Court then announced that strict scrutiny must be ap-
plied to regulations which burden access to contraception:196
[T]he same test must be applied to state regulations that burden
an individual’s right to decide to prevent conception or termi-
nate pregnancy by substantially limiting access to the means of
effectuating that decision as is applied to state statutes that pro-
hibit the decision entirely.  Both types of regulation “may be jus-
tified only by a ‘compelling state interest’ . . . and . . . must be
narrowly drawn to express only the legitimate state interests at
190 Id.
191 431 U.S. 678 (1977).
192 427 F. Supp. 2d 212 (E.D.N.Y. 2006).
193 431 U.S. at 681.
194 Id. at 684–85 (“This right of personal privacy includes ‘the interest in indepen-
dence in making certain kinds of important decisions.’ ” (citing Whalen v. Roe, 429
U.S. 589, 599–600 (1977)). Id. at 684.
195 Id. at 685.
196 Id. at 686–87 (finding the decision to have children fundamental; thus warrant-
ing strict scrutiny analysis, and further that “[r]estrictions on the distribution of con-
traceptives clearly burden the freedom to make such decisions.”) id. at 687.
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stake.”197
The Court emphasized that there is no fundamental right to access
to contraceptives per se, but that “such access is essential to exer-
cise of the constitutionally protected right of decision in matters of
childbearing that is the underlying foundation of the holdings in
Griswold [v. Connecticut], Eisenstadt v. Baird, and Roe v. Wade.”198
The Court importantly noted that “[n]othing in the record sug-
gests that pharmacists are particularly qualified to give advice on
the merits of different nonmedical contraceptives, or that such ad-
vice is more necessary to the purchaser of contraceptive products
than to consumers of other nonprescription items.”199
A plurality of the Court rejected the appellants’ argument that
the statutory provision prohibiting the distribution of contracep-
tives to adolescents less than sixteen years of age was “constitution-
ally permissible as a regulation of the morality of minors, in
furtherance of the State’s policy against promiscuous sexual inter-
course among the young.”200  Instead, the plurality determined
that “[s]tate restrictions inhibiting privacy rights of minors are
valid only if they serve ‘any significant state interest . . . that is not
present in the case of an adult.’”201
Turning to the state interests offered by appellants, the plural-
ity rejected the argument that “significant state interests are served
by restricting minors’ access to contraceptives, because free availa-
bility to minors of contraceptives would lead to increased sexual
activity among the young, in violation of the [state] policy . . . to
discourage such behavior.”202  Thus the plurality declined to adopt
197 Id. at 688 (citing Roe v. Wade, 410 U.S. 113, 155 (1973)).
198 Carey, 431 U.S. at 688–89. See generally Griswold v. Connecticut, 381 U.S. 479,
485–86 (1965) (holding that the right to privacy protects married couples’ decision to
use contraceptives); Eisenstadt v. Baird, 405 U.S. 438, 454–55 (1972) (holding that
the right to privacy in one’s decision to use contraceptives extends to unmarried per-
sons); Roe v. Wade, 410 U.S. 113, 164–65 (1973) (holding that “(a) For the stage
prior to approximately the end of the first trimester, the abortion decision and its
effectuation must be left to the medical judgment of the pregnant woman’s attending
physician. (b) For the stage subsequent to approximately the end of the first trimes-
ter, the State, in promoting its interest in the health of the mother, may, if it chooses,
regulate the abortion procedure in ways that are reasonably related to maternal
health.  (c) For the stage subsequent to viability, the State in promoting its interest in
the potentiality of human life may, if it chooses, regulate, and even proscribe, abor-
tion except where it is necessary, in appropriate medical judgment, for the preserva-
tion of the life or health of the mother.”).
199 Carey, 431 U.S. at 691.
200 Id. at 692–96.
201 Id. at 693 (citing Planned Parenthood of Cent. Mo. v. Danforth, 428 U.S. 52, 75
(1976)).
202 Id. at 694.
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the view that “minors’ sexual activity may be deterred by increasing
the hazards attendant on it.”203  The plurality was particularly con-
cerned with the fact that “[a]ppellants assert no medical necessity for
imposing a medical limitation on the distribution of nonprescrip-
tion contraceptives to minors.”204
B. Rethinking Carey in Light of Plan B’s Age Restriction: Tummino
v. von Eschenbach
In Tummino, the plaintiffs sought a court order directing the
FDA to give Plan B unrestricted over-the-counter status.205  The
plaintiffs charged that:
Only women (and men, for whom Plan B has no approved use)
who are willing to present government-issued identification
proving that they are at least 18 years of age will be able to ob-
tain Plan B from pharmacies without a prescription. Other wo-
men, including all women under 18 and women who either do
not have government-issued proof of age or are unwilling to dis-
play it to pharmacy staff, must have a prescription in order to
obtain Plan B.206
In support of switching Plan B from behind-the-counter to pure
over-the-counter status, the plaintiffs argued that “[t]he approved
instructions for using Plan B can be comprehended adequately by
all women of child-bearing age without the assistance of a physician
or other learned intermediary.”207  The Tummino plaintiffs set forth
four theories which each charged that the behind-the-counter re-
gime was unconstitutional; this Comment will discuss the argument
that the rule’s age restriction violates the constitutional right to de-
cisional privacy.208
203 Id.
204 Id. at 697 (emphasis added).
205 Brief of Plaintiffs, supra note 4.
206 Id. at 1–2.
207 Id. at 9 (citation omitted).
208 The plaintiffs’ remaining three constitutional theories were that the FDA rule
constitutes an impermissible gender-based classification in violation of the equal pro-
tection clause; it violates the fundamental rights branch of the equal protection
clause; and that it violates the constitutional right to informational privacy.  Brief of
Plaintiffs, supra note 4, at 60.  Neither the Tummino plaintiffs nor this author consider
the First Amendment implications of the identification requirement, but this is an-
other theory advocates should pursue. See Watchtower & Bible Tract Soc’y of N.Y. v.
Village of Stratton, 536 U.S. 150, 153, 165–66 (2002) (invalidating ordinance which
makes it a misdemeanor to engage in door-to-door advocacy without first registering
with the mayor and receiving a permit containing canvasser’s name which must be
displayed to residents on demand.  The Court in Watchtower found the ordinance was
unconstitutional because it is “offensive—not only to the values protected by the First
Amendment, but to the very notion of a free society—that in the context of everyday
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The plaintiffs in Tummino argued that Plan B’s age restriction
violates the constitutional right to decisional privacy delineated in
Carey.209  In assessing whether the age restriction meets the test re-
quired by the Carey plurality—that “[s]tate restrictions inhibiting
privacy rights of minors are valid only if they serve any significant
state interest . . . that is not present in the case of an adult”210—the
plaintiffs argued that the government failed to meet this burden
because of the lack of scientific authority regarding the necessity to
restrict behind-the-counter access of Plan B to persons under the
age of eighteen.211  In support of this argument, the plaintiffs
charged, “[s]urely the scientific support for an age restriction can-
not be ‘compelling’ when every major public health organization,
all the internal usual decision makers at FDA, and one of the
world’s leading experts on Plan B all agree that the scientific justifi-
cations for the age restriction are spurious.”212
Next, the plaintiffs argued that, even if the government’s argu-
ment that the age restriction is supported by a significant state in-
terest to protect public health, the behind-the-counter regime is
not narrowly tailored to that state interest.213  This is because:
[A]llowing men [eighteen] and over to buy Plan B without a
prescription, while simultaneously restricting the availability of
Plan B so severely for women of all ages, as the [behind-the-
counter] regime does, is so hopelessly unrelated to any scientific
evidence or other possible justification that it renders the entire
regime a travesty.214
This argument highlights one of the most problematic aspects of
the rule.  That is, the age restriction allows male non-users over the
age of eighteen to purchase the drug, while limiting female users
under the age of eighteen to access the drug only with a doctor’s
prescription.  In doing so, “[t]he FDA’s rejection of unrestricted
OTC status for Plan B and the structure of the BTC regime both
perpetuate outmoded stereotypes of women as less capable of mak-
ing rational judgments than men and as incapable of following
simple instructions.”215  Feminists must persistently challenge these
types of stereotypes—especially to the extent that they purport to
public discourse a citizen must first inform the government of her desire to speak to
her neighbors and then obtain a permit to do so.”).
209 Brief of Plaintiffs, supra note 4, at 62.
210 Carey, 431 U.S. at 693 (internal quotation omitted).
211 Brief of Plaintiffs, supra note 4, at 64.
212 Id.
213 Id. at 65.
214 Id. at 66.
215 Id. at 44–45 (citations omitted).
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be “neutral.”  That is, the fact that anyone, male or female, over the
age of eighteen can purchase Plan B without a prescription is in
fact highly gendered.
The age restriction perpetuates sexist stereotypes in two ways.
First, it holds young women solely responsible for sexual activity
shared with a partner.216  Analogously, in making its determination
that young women needed to be deterred from “promiscuous” be-
havior, the FDA impermissibly considered the drug’s impact on
personal behavior—something the FDA has never done in review-
ing switch applications.217  This is not unlike Kansas Attorney Gen-
eral Phil Kline’s interpretation of a child-abuse-reporting statute
known as the “Kiss and Tell” law.218  The interpretation primarily
operated to ascribe shame to young sexually active women by re-
quiring health care professionals to report their adolescent pa-
tients to the state whenever the professional suspected the patient
was sexually active—regardless of whether the professional be-
lieved such activity constituted abuse.  As Buchanan argues,
“[a]lthough the [Kiss and Tell] regulation nominally applied to
both young women and young men, this restriction disproportion-
ately exposes sexually active young women to governmental surveil-
lance and punishment.”219  Both the Kansas “Kiss and Tell” law and
the age restriction attached to Plan B’s behind-the-counter regime
are illustrative of the way in which “[t]he explicit pairing of law and
216 Fine & McClelland, supra note 185, at 1014-15 (“[T]he continued restrictions of
young women’s access highlights one of the important ways that young women are
held solely responsible for the consequences of sexual activity. With the new FDA
decision, a young woman who experiences unplanned or forced sexual intercourse
must first see a doctor (at her own cost) to obtain a prescription during the 72-hour
window when emergency contraception is most effective; second, she must find a
pharmacist who is willing to fill the prescription; and third, she must pay for the drug
(again, at her own cost).”).
217 Brief of Plaintiffs, supra note 4, at 43 (“The FDA cannot identify another occa-
sion in which it considered how its approval of a drug would effect on personal behav-
ior of those who would use it. Indeed, the FDA did not consider the effects on sexual
behavior of men when it approved Viagra and other erectile dysfunction drugs, and
approved Plan B itself as a nonprescription drug for sale to men 18 and over without
any data concerning, much less consideration of, the effect it might have on the sex-
ual or contraceptive behavior of such men.”) (internal citations omitted). See also
Buchanan, supra note 8, at 1264 (“The unprecedented delay in the agency decision-
making process and the eventual age requirement rested, at least in part, on concern
expressed by political appointees on the FDA panel that nonprescription availability
of the morning-after pill might lead to ‘promiscuity’ among young women.”).
218 See Kan. Op. Att’y Gen. No. 2003-17 (June 18, 2003), available at http://ksag.
washburnlaw.edu/opinions/2003/2003-017.htm (last visited Mar. 10, 2008).  Kan.
Stat. Ann. § 38-1522 (2006).  The statute was enjoined in Aid for Women v. Foulston, 427
F. Supp. 2d 1093, 1116 (D. Kan. 2006) (order granting permanent injunction.
219 Buchanan, supra note 8, at 1267.
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religious ideology has transformed the role of law and public policy
in young women’s lives from a supportive function to one that cen-
sures young women for their sexual behavior.”220
Second, the age restriction reflects sexist stereotypes in that it
suggests that men—so long as they are over the age of eighteen—
are somehow more capable than minor women or women without
the required identification of making the decision to purchase
Plan B, although men are not approved for actual use of the
drug.221  The way in which the behind-the-counter scheme privi-
leges the male non-user/purchaser over the adolescent user sup-
ports MacKinnon’s argument that “the theme of the laws of . . .
reproduction is male control of, access to, and use of women,”222 in
that allowing men to purchase Plan B, which they will then pass on
to the female user, ascribes to men a certain degree of power in the
process.  This critique of the age restriction is feminist, then, in
that it is “skeptical of the traditions, conventions, and customs that
shape the sex and family roles of men and women.”223
Ensuring timely access to emergency contraception for women
of all ages is crucial in order to reduce unwanted pregnancies and
to provide appropriate support and services to rape victims.  Mak-
ing Plan B available over-the-counter is particularly important for
young women and poor women.224  Psychology professor Michelle
Fine and graduate student Sara McClelland eloquently summarize
why reproductive rights advocates should not ignore the gendered
implications of the age restriction:
What seems evident from the FDA decision is that public ambiv-
alence about young women’s sexuality was used as a way of re-
stricting the reproductive choices for all women. This is not a
small point. It signals how young women are increasingly being
220 Fine & McClelland, supra note 185, at 995.
221 See Brief of Plaintiffs, supra note 4, at 46 (“[B]y rejecting as insufficient evidence
that non-prescription availability of Plan B would not affect adolescent women detri-
mentally by changing their contraceptive behavior, while simultaneously approving
non-prescription availability of Plan B for adult men without any studies showing how
availability affects men’s sexual behavior, the BTC regime reinforces an outmoded
stereotype of women as less capable than men of making their own sexual and contra-
ceptive decisions.”).
222 MacKinnon, supra note 50, at 1301.
223 Siegel, supra note 51, at 817.
224 See Buchanan, supra note 8, at 1256–57 (“The young and poor women who face
the greatest stigma for sexual activity and the highest barriers to access and informa-
tion about contraception and abortion also have the highest rates of unintended
pregnancy, abortion, and unintended birth.”) (relying on Lawrence B. Finer & Stan-
ley K. Henshaw, Disparities in Rates of Unintended Pregnancy in the United States, 1994 and
2001, 38 PERSP. ON SEXUAL & REPROD. HEALTH 90, 93–94 (2006).
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used to reinscribe female sexual behavior as inappropriate and
dangerous at the same time as access to contraception is being
curtailed.  Young women were used as a lightning rod in con-
structing the story of how Plan B would “increase promiscuity”
or affect sexual risk taking, thereby limiting access to a form of
contraception that has been proven safe and effective. The ex-
ample of Plan B should serve to illustrate how young women’s
sexuality is increasingly described as dangerous and their sexual
and reproductive freedoms constricted. Young women’s rights
should serve as a warning to all women; the same arguments that
are used today to circumscribe the sexual rights of adolescents
can (and have already been) used to circumscribe the rights of
all women tomorrow.225
In the preceding passage, the authors make an important point
that the age restriction did not occur in a vacuum; it occurred at a
time in which the sexual rights of women are persistently being
undermined by an administration that prioritizes politics and ide-
ology over women’s health.
In identifying and analyzing two of the behind-the-counter
rule’s shortcomings—the way in which it allows for pharmacist re-
fusals, and the way in which it violates young women’s right to deci-
sional privacy—this Comment attempts to provide litigation
strategies that are responsive to the varying degrees to which a wo-
man affected by the rule can be involved.  At the same time, this
Comment attempts to incorporate a feminist legal perspective into
the conversation about the inadequacy of the behind-the-counter
rule in order to highlight, in particular, the ways in which both
governmental and private decision-making are imbued with tradi-
tional notions about women and sexuality.  In a culture in which a
court held that a pharmacist’s refusal to provide women with ur-
gently-needed medication “has nothing to do with gender or gen-
der discrimination,”226 it is even more important that feminist legal
activists challenge affronts to reproductive choice in increasingly
innovative ways.
225 Fine & McClelland, supra note 185, at 1017–18 (emphasis added) (citation
omitted).
226 Stormans, 524 F. Supp. 2d 1245, 1263 (W.D. Wash. 2007).

